Completed PHASE1 INTERVENTIONAL 1-arm NCT03643614

Autologous Adipose-derived Regenerative Cells Injection for Treatment of Radiation-induced Rectovaginal Fistula

Evaluation of Effectiveness and Safety of Autologous Adipose-derived Regenerative Cells Injection for Treatment of Radiation-induced Rectovaginal Fistula

Sponsor: South Ural State Medical University

Conditions Rectovaginal Fistula

Interventions Injection of autologous regenerative cells of adipose tissue

Updated 8 times since 2018 Last updated: Jan 23, 2020 Started: Aug 1, 2017 Primary completion: Nov 15, 2019 Completion: Jan 22, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Rectovaginal Fistula and is currently completed. South Ural State Medical University leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

Dec 2019 — Feb 2020 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jan 2019 — Dec 2019 [monthly]

Recruiting PHASE1
Sep 2018 — Jan 2019 [monthly]

Recruiting PHASE1

First recorded

Aug 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

South Ural State Medical University

Data source: South Ural State Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chelyabinsk, Russia